Jaguar Health, Inc. (JAGX) Sets 1 Year Low; Strong Momentum for Sellers

July 16, 2018 - By Lisa Delgado

Jaguar Health, Inc. (NASDAQ:JAGX) Logo

The stock of Jaguar Health, Inc. (NASDAQ:JAGX) hit a new 52-week low and has $1.19 target or 6.00 % below today’s $1.27 share price. The 5 months bearish chart indicates high risk for the $14.51 million company. The 1-year low was reported on Jul, 16 by If the $1.19 price target is reached, the company will be worth $870,360 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 7.31% or $0.1001 during the last trading session, reaching $1.2699. About 243,169 shares traded. Jaguar Health, Inc. (NASDAQ:JAGX) has declined 79.10% since July 16, 2017 and is downtrending. It has underperformed by 91.67% the S&P500.

More notable recent Jaguar Health, Inc. (NASDAQ:JAGX) news were published by: which released: “Your Daily Pharma Scoop: Redhill’s New Patent, Nuvectra Slips, Teligent Gains” on July 03, 2018, also with their article: “44 Biggest Movers From Yesterday” published on July 13, 2018, published: “Research Report Identifies Glu Mobile, Reliance Steel & Aluminum, FedEx, Jaguar Animal Health, Box, and VirnetX …” on June 25, 2018. More interesting news about Jaguar Health, Inc. (NASDAQ:JAGX) were released by: and their article: “Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference” published on July 16, 2018 as well as‘s news article titled: “Jaguar Health (JAGX) Reports Q2 Financial Updates” with publication date: July 12, 2018.

Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company has market cap of $14.51 million. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. It currently has negative earnings. The Company’s human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome – diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.